+关注
拒绝跪舔
暂无个人介绍
IP属地：湖北
0
关注
0
粉丝
0
主题
0
勋章
主贴
热门
拒绝跪舔
04-11
垃圾
百济神州下跌2.18%，报146.5美元/股
拒绝跪舔
04-10
垃圾
《大行》美银证券降百济神州(06160.HK)目标价至99.21元 评级“中性”
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3568033630553262,"uuid":"3568033630553262","gmtCreate":1604939607119,"gmtModify":1645638492846,"name":"拒绝跪舔","pinyin":"jjgtjujueguitian","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/55f01e2eac2408ade76a32f5624540a2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"湖北","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":294202079531088,"gmtCreate":1712849807295,"gmtModify":1712850739450,"author":{"id":"3568033630553262","authorId":"3568033630553262","name":"拒绝跪舔","avatar":"https://static.tigerbbs.com/55f01e2eac2408ade76a32f5624540a2","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"垃圾","listText":"垃圾","text":"垃圾","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/294202079531088","repostId":"2426692332","repostType":2,"repost":{"id":"2426692332","pubTimestamp":1712847394,"share":"https://www.laohu8.com/m/news/2426692332?lang=&edition=full","pubTime":"2024-04-11 22:56","market":"sh","language":"zh","title":"百济神州下跌2.18%，报146.5美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426692332","media":"金融界","summary":"4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","content":"<html><body><div>\n<p>4月11日，<span><a href=\"https://laohu8.com/S/688235\">百济神州</a></span>(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。</p><p>财务数据显示，截至2023年12月31日，<a href=\"https://laohu8.com/S/06160\">百济神州</a>收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。</p><p>大事提醒：</p><p>4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。</p><p>5月2日，百济神州将披露2024财年一季报。</p>\n<div>\n<div>\n</div>\n</div>\n</div></body></html>","source":"jinrongjie_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州下跌2.18%，报146.5美元/股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州下跌2.18%，报146.5美元/股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 22:56 北京时间 <a href=https://usstock.jrj.com.cn/2024/04/11225640205824.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。</p>\n\n<a href=\"https://usstock.jrj.com.cn/2024/04/11225640205824.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4588":"碎股","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1588":"回港中概股","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BGNE":"百济神州","BK4505":"高瓴资本持仓","06160":"百济神州","BK4139":"生物科技","BK1500":"做空集合股"},"source_url":"https://usstock.jrj.com.cn/2024/04/11225640205824.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2426692332","content_text":"4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":293787772624904,"gmtCreate":1712756050812,"gmtModify":1712756509572,"author":{"id":"3568033630553262","authorId":"3568033630553262","name":"拒绝跪舔","avatar":"https://static.tigerbbs.com/55f01e2eac2408ade76a32f5624540a2","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"垃圾","listText":"垃圾","text":"垃圾","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/293787772624904","repostId":"2426048188","repostType":2,"repost":{"id":"2426048188","pubTimestamp":1712721660,"share":"https://www.laohu8.com/m/news/2426048188?lang=&edition=full","pubTime":"2024-04-10 12:01","market":"us","language":"zh","title":"《大行》美银证券降百济神州(06160.HK)目标价至99.21元 评级“中性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2426048188","media":"阿斯达克财经","summary":"美银证券发表研究报告指，百济神州自研药物帕米帕利2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。","content":"<html><body><div> <span> <p>美银证券发表研究报告指，<a href=\"https://laohu8.com/S/688235\">百济神州</a>(06160.HK)<span> </span>自研药物帕米帕利(Pamiparib)2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗(Tislelizumab)、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。<br/><span></span><br/>该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》美银证券降百济神州(06160.HK)目标价至99.21元 评级“中性”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》美银证券降百济神州(06160.HK)目标价至99.21元 评级“中性”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 12:01 北京时间 <a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美银证券发表研究报告指，百济神州(06160.HK) 自研药物帕米帕利(Pamiparib)2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗(Tislelizumab)、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210201153351459_s.jpg","relate_stocks":{"161027":"证券","688235":"百济神州","06160":"百济神州","BGNE":"百济神州"},"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2426048188","content_text":"美银证券发表研究报告指，百济神州(06160.HK) 自研药物帕米帕利(Pamiparib)2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗(Tislelizumab)、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。)AASTOCKS新闻","news_type":1},"isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":294202079531088,"gmtCreate":1712849807295,"gmtModify":1712850739450,"author":{"id":"3568033630553262","authorId":"3568033630553262","name":"拒绝跪舔","avatar":"https://static.tigerbbs.com/55f01e2eac2408ade76a32f5624540a2","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"垃圾","listText":"垃圾","text":"垃圾","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/294202079531088","repostId":"2426692332","repostType":2,"repost":{"id":"2426692332","pubTimestamp":1712847394,"share":"https://www.laohu8.com/m/news/2426692332?lang=&edition=full","pubTime":"2024-04-11 22:56","market":"sh","language":"zh","title":"百济神州下跌2.18%，报146.5美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426692332","media":"金融界","summary":"4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","content":"<html><body><div>\n<p>4月11日，<span><a href=\"https://laohu8.com/S/688235\">百济神州</a></span>(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。</p><p>财务数据显示，截至2023年12月31日，<a href=\"https://laohu8.com/S/06160\">百济神州</a>收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。</p><p>大事提醒：</p><p>4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。</p><p>5月2日，百济神州将披露2024财年一季报。</p>\n<div>\n<div>\n</div>\n</div>\n</div></body></html>","source":"jinrongjie_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州下跌2.18%，报146.5美元/股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州下跌2.18%，报146.5美元/股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 22:56 北京时间 <a href=https://usstock.jrj.com.cn/2024/04/11225640205824.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。</p>\n\n<a href=\"https://usstock.jrj.com.cn/2024/04/11225640205824.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4588":"碎股","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1588":"回港中概股","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BGNE":"百济神州","BK4505":"高瓴资本持仓","06160":"百济神州","BK4139":"生物科技","BK1500":"做空集合股"},"source_url":"https://usstock.jrj.com.cn/2024/04/11225640205824.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2426692332","content_text":"4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":293787772624904,"gmtCreate":1712756050812,"gmtModify":1712756509572,"author":{"id":"3568033630553262","authorId":"3568033630553262","name":"拒绝跪舔","avatar":"https://static.tigerbbs.com/55f01e2eac2408ade76a32f5624540a2","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"垃圾","listText":"垃圾","text":"垃圾","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/293787772624904","repostId":"2426048188","repostType":2,"repost":{"id":"2426048188","pubTimestamp":1712721660,"share":"https://www.laohu8.com/m/news/2426048188?lang=&edition=full","pubTime":"2024-04-10 12:01","market":"us","language":"zh","title":"《大行》美银证券降百济神州(06160.HK)目标价至99.21元 评级“中性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2426048188","media":"阿斯达克财经","summary":"美银证券发表研究报告指，百济神州自研药物帕米帕利2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。","content":"<html><body><div> <span> <p>美银证券发表研究报告指，<a href=\"https://laohu8.com/S/688235\">百济神州</a>(06160.HK)<span> </span>自研药物帕米帕利(Pamiparib)2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗(Tislelizumab)、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。<br/><span></span><br/>该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》美银证券降百济神州(06160.HK)目标价至99.21元 评级“中性”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》美银证券降百济神州(06160.HK)目标价至99.21元 评级“中性”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 12:01 北京时间 <a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美银证券发表研究报告指，百济神州(06160.HK) 自研药物帕米帕利(Pamiparib)2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗(Tislelizumab)、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210201153351459_s.jpg","relate_stocks":{"161027":"证券","688235":"百济神州","06160":"百济神州","BGNE":"百济神州"},"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2426048188","content_text":"美银证券发表研究报告指，百济神州(06160.HK) 自研药物帕米帕利(Pamiparib)2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗(Tislelizumab)、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。)AASTOCKS新闻","news_type":1},"isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
